Clinical trial NCT02039505: Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis
Official title: Phase III, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intravenous MLN0002 (300 mg) Infusion in Induction and Maintenance Therapy in Japanese Subjects With Moderate or Severe Ulcerative Colitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Ulcerative Colitis
Keywords: Drug therapy
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2014-01-17
Enrollment: 292
Sex: ALL
Minimum age (years): 15
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate efficacy, safety and pharmacokinetics of the vedolizumab (MLN0002) induction and maintenance therapy in Japanese participants with moderate or severe ulcerative colitis (UC).

Detailed description: This study is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to examine the efficacy, safety, and pharmacokinetics of MLN0002 (Vedolizumab) in induction and maintenance therapy in Japanese patients with moderately or severely active ulcerative colitis.

Eligibility criteria: Inclusion Criteria:

1. In the opinion of the investigator, a participant is capable of understanding and complying with protocol requirements.
2. A participant who is capable of entering the signature and the date on the informed consent by himself/herself or by the participant's legally acceptable representative, if applicable, prior to initiation of study procedures.
3. A participant aged 15 to 80 (inclusive) at the time of signing the informed consent (regardless of sexes).
4. A male participant, who has no sterilization history and whose female partner has child-bearing potential, who agreed with taking proper contraception during the period from the time of signing the informed consent form through 6 months after the last dose of study drug.
5. A female participant with child-bearing potential (having no history of sterilization or whose last menstruation was within 2 years) whose male partner is not receiving contraceptive treatment, and agreed to take proper contraception during the period from the time of signing on the informed consent form through 6 months after the last dose of the study drug.
6. Participants with diagnosis of total or left-sided ulcerative colitis (UC) based on the Revised Diagnostic Criteria for UC issued by "Research Group for Intractable Inflammatory Bowel Disease Designated as Specified Disease" by the Ministry of Health, Labor and Welfare (MHLW) of Japan (2012) at least 6 months before the start of administration of the study drug.
7. A participant with moderately or severely active UC as determined by baseline complete Mayo score of 6 to 12 (inclusive) with an endoscopic subscore of ≥2.
8. Participants whose complication of colon cancer or dysplasia had to be ruled out by total colonoscopy at the start of the study drug administration (or the results from total colonoscopy performed within 1 year before giving consent are available), if participants met any of the following criteria; participants with ≥8-year history of total or left-sided colitis, participants aged ≥50 years, or participants with a first-degree family history of colon cancer.
9. Participants meeting the following treatment failure criteria with at least one of the following agents within 5 years before signing on the informed consent:

   1. Corticosteroids

      * Resistance: Participants whose response was inadequate after treatment of ≥40 mg/day for ≥1 week (oral or IV) or 30 to 40 mg/day for ≥2 weeks (oral or IV).
      * Dependence: Participants for which it is difficult to reduce the dosage to \<10 mg/day due to recurrence during gradual dose reduction (oral or IV).
      * Intolerance: Participants who were unable to receive continuous treatment due to adverse reactions (e.g., Cushing's syndrome, osteopenia/osteoporosis, hyperglycaemia, insomnia, infection).
   2. Immunomodulators (azathioprine \[AZA\] or 6- mercaptopurine \[6-MP\])

      * Refractory: Participants whose response was inadequate after treatment for ≥12 weeks.
      * Intolerance: Participants who were unable to receive continuous treatment due to adverse reactions (e.g., nausea/vomiting, abdominal pain, pancreatitis, liver function test abnormalities, lymphopenia, thiopurine S-methyltransferase genetic mutation, infection).
   3. Tumor necrosis factor-alpha (TNFα) antagonist

      * Inadequate response: Participants whose response was inadequate after the induction therapy in the dosage described in the package insert.
      * Loss of response: Participants who had recurrence during the scheduled maintenance therapy after achievement of clinical response (those who withdrew for other reasons than relapse are not applicable here).
      * Intolerance: Participants who were unable to receive continuous treatment due to adverse reactions (eg, infusion-related reaction, demyelination, congestive heart failure, infection).

Exclusion Criteria:

1. Participants whose partial Mayo score decrease by 3 points or more between screening and the start of study drug administration.
2. Participants having or suspected to have abdominal abscess or toxic megacolon.
3. Participants with a history of subtotal or total colectomy.
4. Participants with ileostomy, colostomy, fistula or severe intestinal stenosis.
5. Participants having a treatment history with natalizumab, efalizumab or rituximab.
6. Participants who started oral 5-ASA, probiotics, or oral corticosteroids (≤30 mg/day) within 13 days before the first dose of the study drug. Participants who have used these drugs for at least 14 days before the first dose of the study drug, and who changed dosage of or discontinued these drugs within 13 days before the first dose of the study drug.
7. Participants who have received 5-ASA, corticosteroid enemas/suppositories, corticosteroid IV infusion, oral corticosteroid at \>30 mg/day, drugs for diarrhea-predominant irritable bowel syndrome, or Chinese herbal medicine for the UC treatment (eg, Daikenchuto) within 13 days before the first dose of the study drug.
8. Participants who have used an antidiarrheal drug for 4 or more consecutive days within 13 days before the first dose of the study drug or within 7 days before the first dose of the study drug.
9. Participants who have received AZA or 6-MP within 27 days before the first dose of the study drug However, this will not apply to participants who have used these drugs for 83 or more days before the first dose of the study drug and continued the steady dose administration of the drugs for 27 or more days before the first dose of the study drug.
10. Participants who have received cyclosporine, tacrolimus, methotrexate, tofacitinib or any study drugs of low-molecular compound for UC treatment within 27 days before the first dose of the study drug.
11. Participants who have received adalimumab within 27 days before the first dose of the study drug or any biologic agents other than adalimumab within 55 days before the first dose of the study drug. However, this will not apply to participants who have topically received these drugs (eg., intraocular injection for treatment of age-related macular degeneration).
12. Participants who have received any live-vaccinations within 27 days before the first dose of the study drug.
13. Participants who underwent the enterectomy within 27 days before the first dose of the study drug or those anticipated to require an enterectomy during the study.
14. Participants who have received leukocytapheresis or granulocyte apheresis within 27 days before the first dose of the study drug.
15. Participants who have been infected with an intestinal pathogen including clostridium difficile or cytomegalovirus within 27 days before the first dose of the study drug.
16. Participants with evidence of adenomatous colonic polyps that need to be removed at the start of study drug administration.
17. Participants with a history or a complication of colonic mucosal dysplasia.
18. Participants suspected to have enteritis other than UC.
19. Participants indicated in the screening test as hepatitis B surface (HBs) antigen-positive or hepatitis C virus (HCV) antibody-positive. Participants indicated as hepatitis B core (HBc) antibody-positive or HBs antibody positive even though HBs antigen-negative However, the criteria will not apply to those with only HBs antibody-positive due to hepatitis B virus (HBV) vaccination, HBV-DNA-negative, HCV antigen-negative or HCV-RNA-negative.
20. Participants who have or are suspected to have a history of tuberculosis (including those whose findings in the chest imaging procedure at screening showing anamnesis of tuberculosis). However, the criteria will not apply to those who had completed prophylactic treatment with isoniazid, and who have been receiving prophylactic isoniazid for 21 days or longer before the first dose of the study drug (the latter may initiate study drug administration with screening phase extended to 28 days at maximum for prophylactic treatment to become 21 days or more).
21. Participants indicated as positive in T-SPOT or QuantiFERON at screening test.
22. Participants who have a history or complication of identified congenital or acquired immunodeficiency syndrome (eg, not-classifiable immunodeficiency, human immunodeficiency virus \[HIV\] infection or organ transplantation).
23. Participants who were affected by extra-intestinal infection (eg, pneumonia, sepsis, active hepatitis or pyelonephritis) within 27 days before the first dose of the study drug.
24. Participants who have treatment history with MLN0002.
25. Nursing mothers during the screening phase, or female participants indicated positive in urine pregnancy test either at the screening or baseline.
26. Participants having serious complications in the heart, lung, liver, kidney, metabolism, gastrointestinal system, urinary system, endocrine system or blood.
27. Participants with a history of an operation requiring general anesthesia within 27 days before the first dose of the study drug, or with a schedule of an operation requiring hospitalization during the study period.
28. Participants having a complication or a history of malignancy However, it will not apply to the following participants;

    * Participants who had a curative resection of localized skin basal cell carcinoma or had completed curative radiotherapy.
    * Participants who have not experienced recurrence for 1 year or longer since completion of curative resection or curative radiotherapy for skin squamous cell carcinoma.
    * Participants who have not experienced recurrence for 3 year or longer since completion of curative resection or curative radiotherapy for intraepithelial carcinoma of uterine cervix.

    For participants having a substantially distant history of malignancy (eg, 10 years or longer without recurrence since treatment completion), the Investigator and the sponsor will discuss to decide eligibility on the basis of type of malignancy and treatment applied.
29. Participants having a history or a complication of the central nervous disorder, including stroke, multiple sclerosis, brain tumor, or neurodegenerative disease.
30. Participants for which any subjective symptoms in the Subjective PML checklist were found at the screening or baseline.
31. Participants for which any of the following laboratory abnormalities were found at the screening;

    * Hemoglobin ≤8 g/dL
    * White blood cells ≤3,000/μL
    * Lymphocytes ≤500/μL
    * Platelets ≤100,000/μL, or ≥1,200,000/μL
    * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3×upper limit of normal (ULN)
    * Alkaline phosphatase (ALP) ≥3×ULN
    * Creatinine ≥2×ULN
32. Participants having a history or a complication of alcohol dependence or illicit drug use within one year before the first dose of the study drug.
33. Participants having a history or a complication of psychotic disorder that may obstruct compliance with the study procedures.

Primary outcomes:
measure: Percentage of Participants With a Clinical Response at Week 10 in Induction Phase
timeFrame: Week 10
measure: Percentage of Participants With Clinical Remission at Week 60 in Maintenance Phase
timeFrame: Week 60
measure: Number of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Events (TEAEs)
timeFrame: From Baseline to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
measure: Number of Participants With TEAE Related to Body Weight
timeFrame: From Baseline to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
measure: Number of Participants With TEAE Related to Vital Signs
timeFrame: From Baseline to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
measure: Number of Participants With TEAE Related to Electrocardiogram (ECG)
timeFrame: From Baseline to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
measure: Number of Participants With Markedly Abnormal Laboratory Parameters Values
timeFrame: From Baseline to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Secondary outcomes:
measure: Percentage of Participants With Clinical Remission at Week 10 in Induction Phase
timeFrame: Week 10
measure: Percentage of Participants With Mucosal Healing at Week 10 in Induction Phase
timeFrame: Week 10
measure: Percentage of Participants With Durable Clinical Response in Maintenance Phase
timeFrame: Weeks 10 and 60
measure: Percentage of Participants With Mucosal Healing at Week 60 in Maintenance Phase
timeFrame: Week 60
measure: Percentage of Participants With Durable Remission in Maintenance Phase
timeFrame: Weeks 10 and 60
measure: Percentage of Participants With Corticosteroid-Free Remission at Week 60 in Maintenance Phase
timeFrame: Week 60
measure: Serum Vedolizumab Concentration in Induction Phase
timeFrame: Pre-dose at Weeks 2, 6, 10 and 14
measure: Serum Vedolizumab Concentration in Maintenance Phase
timeFrame: Pre-dose at Weeks 2, 6, 10, 14, 22, 30 and 60
measure: Number of Participants With Anti-vedolizumab Antibodies (AVA) in Induction Phase
timeFrame: Weeks 0, 10 and 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
measure: Number of Participants With Anti-vedolizumab Antibodies (AVA) in Maintenance Phase
timeFrame: Weeks 0, 10, 30, 60 and 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
measure: Number of Participants With Neutralizing Anti-vedolizumab Antibodies (AVA) in Induction Phase
timeFrame: Weeks 0, 10 and 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
measure: Number of Participants With Neutralizing Anti-vedolizumab Antibodies (AVA) in Maintenance Phase
timeFrame: Weeks 0, 10, 30, 60 and 16 weeks after the last dose of study drug (Up to approximately 170 weeks)
Other outcomes:
Locations:
city: Kasugai-shi
country: Japan
state: Aichi
city: Nagoya-shi
country: Japan
state: Aichi
city: Toyota-shi
country: Japan
state: Aichi
city: Hirosaki-shi
country: Japan
state: Aomori
city: Sakura-shi
country: Japan
state: Chiba
city: Matsuyama-shi
country: Japan
state: Ehime
city: Fukui-shi
country: Japan
state: Fukui
city: Chikushino-shi
country: Japan
state: Fukuoka
city: Fukuoka-shi
country: Japan
state: Fukuoka
city: Kitakyushu-shi
country: Japan
state: Fukuoka
city: Kurume-shi
country: Japan
state: Fukuoka
city: Fukuyama-shi
country: Japan
state: Hiroshima
city: Hatsukaichi-shi
country: Japan
state: Hiroshima
city: Hiroshima-shi
country: Japan
state: Hiroshima
city: Asahikawa-shi
country: Japan
state: Hokkaido
city: Hakodate-shi
country: Japan
state: Hokkaido
city: Sapporo-shi
country: Japan
state: Hokkaido
city: Tomakomai-shi
country: Japan
state: Hokkaido
city: Akashi-shi
country: Japan
state: Hyogo
city: Himeji-shi
country: Japan
state: Hyogo
city: Itami-shi
country: Japan
state: Hyogo
city: Kobe-shi
country: Japan
state: Hyogo
city: Nishinomiya-shi
country: Japan
state: Hyogo
city: Komatsu-shi
country: Japan
state: Ishikawa
city: Marukame-shi
country: Japan
state: Kagawa
city: Takamatsu-shi
country: Japan
state: Kagawa
city: Kagoshima-shi
country: Japan
state: Kagoshima
city: Fujisawa-shi
country: Japan
state: Kanagawa
city: Kamakura-shi
country: Japan
state: Kanagawa
city: Kawasaki-shi
country: Japan
state: Kanagawa
city: Sagamihara-shi
country: Japan
state: Kanagawa
city: Yokohama-shi
country: Japan
state: Kanagawa
city: Kochi-shi
country: Japan
state: Kochi
city: Kumamoto-shi
country: Japan
state: Kumamoto
city: Kyoto-shi
country: Japan
state: Kyoto
city: Sendai-shi
country: Japan
state: Miyagi
city: Nagasaki-shi
country: Japan
state: Nagasaki
city: Beppu-shi
country: Japan
state: Ohita
city: Oita
country: Japan
state: Ohita
city: Okayama-shi
country: Japan
state: Okayama
city: Moriguchi-shi
country: Japan
state: Osaka
city: Osaka-shi
country: Japan
state: Osaka
city: Sakai-shi
country: Japan
state: Osaka
city: Suita-shi
country: Japan
state: Osaka
city: Saga-shi
country: Japan
state: Saga
city: Tokorozawa-shi
country: Japan
state: Saitama
city: Otsu
country: Japan
state: Shiga
city: Hamamatsu-shi
country: Japan
state: Shizuoka
city: Shimotsuke-shi
country: Japan
state: Tochigi
city: Adachi-ku
country: Japan
state: Tokyo
city: Bunkyo-ku
country: Japan
state: Tokyo
city: Chiyoda-ku
country: Japan
state: Tokyo
city: Edogawa
country: Japan
state: Tokyo
city: Minato-ku
country: Japan
state: Tokyo
city: Shinagawa-ku
country: Japan
state: Tokyo
city: Shinjuku-ku
country: Japan
state: Tokyo
city: Wakayama-shi
country: Japan
state: Wakayama
city: Shunan-shi
country: Japan
state: Yamaguchi
city: Kofu-shi
country: Japan
state: Yamanashi
Study officials:
affiliation: Takeda
name: Study Director
role: STUDY_DIRECTOR
References:
citation: Naganuma M, Watanabe K, Motoya S, Ogata H, Matsui T, Suzuki Y, Ursos L, Sakamoto S, Shikamura M, Hori T, Fernandez J, Watanabe M, Hibi T, Kanai T. Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis. J Gastroenterol Hepatol. 2022 Jan;37(1):81-88. doi: 10.1111/jgh.15667. Epub 2021 Sep 7.
citation: Nagahori M, Watanabe K, Motoya S, Ogata H, Kanai T, Matsui T, Suzuki Y, Pinton P, Ursos L, Sakamoto S, Shikamura M, Hori T, Fernandez J, Hibi T, Watanabe M. Week 2 Symptomatic Response with Vedolizumab as a Predictive Factor in Japanese Anti-TNFalpha-Naive Patients with Ulcerative Colitis: A post hoc Analysis of a Randomized, Placebo-Controlled Phase 3 Trial. Digestion. 2021;102(5):742-752. doi: 10.1159/000512235. Epub 2021 Jan 15.
citation: Okamoto H, Dirks NL, Rosario M, Hori T, Hibi T. Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn's disease. Intest Res. 2021 Jan;19(1):95-105. doi: 10.5217/ir.2019.09167. Epub 2020 Jul 10.
citation: Motoya S, Watanabe K, Ogata H, Kanai T, Matsui T, Suzuki Y, Shikamura M, Sugiura K, Oda K, Hori T, Araki T, Watanabe M, Hibi T. Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. PLoS One. 2019 Feb 26;14(2):e0212989. doi: 10.1371/journal.pone.0212989. eCollection 2019.